Actavis Standard Transcends Cash Deals, FTC Tells 3rd Circ.
By Allissa Wickham ( April 29, 2014, 3:21 PM EDT) -- The Federal Trade Commission on Monday urged the Third Circuit to revive a proposed antitrust class action against GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. over a deal to postpone generics of epilepsy drug Lamictal, arguing that cash isn't the only form of compensation prohibited under a recent U.S. Supreme Court ruling on pay-for-delay agreements....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.